Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation in PALLAS.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Clin Oncol

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publisher: American Society of Clinical Oncology (ASCO)

ISSN (Electronic): 1527-7755

ISSN (Print): 0732-183X

Publication date (Electronic): February 10 2022

Volume: 40

Issue: 5

Affiliations

[1 ] Dana-Farber Cancer Institute, Boston, MA.

[2 ] Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.

[3 ] MD Anderson Cancer Center, Madrid, Spain.

[4 ] GEICAM Spanish Breast Cancer Group, Madrid, Spain.

[5 ] The Breast and Endocrine Centre, Gateshead, NSW, Australia.

[6 ] Breast Centre, Sankt Veit an der Glan, Austria.

[7 ] Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.

[8 ] Medical University Graz, Graz, Austria.

[9 ] Vanderbilt University, Nashville, TN.

[10 ] Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom.

[11 ] Hospital General Universitario de Alicante, Alicante, Spain.

[12 ] Memorial Sloan Kettering Cancer Center, New York, NY.

[13 ] Mayo Clinic, Rochester, MN.

[14 ] Queen's University, Kingston, Canada.

[15 ] Aichi Cancer Center Hospital, Aichi, Japan.

[16 ] Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisboa, Portugal.

[17 ] Lakeside Specialist Breast Clinic and Nepean Cancer Care Centre, Norwest, NSW, Australia.

[18 ] Brust-Zentrum, Zürich, Switzerland.

[19 ] Alliance Foundation Trials, Boston, MA.

[20 ] Breast International Group, Brussels, Belgium.

[21 ] Pfizer, Inc, Cambridge, MA.

[22 ] Pfizer, Inc, La Jolla, CA.

[23 ] Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ.

[24 ] Medical University of Vienna, Vienna, Austria.

[25 ] Penn Medicine, Philadelphia, PA.

Article

DOI: 10.1200/JCO.21.01918

PubMed ID: 34995105

SO-VID: 74eb578d-da73-453c-9594-772731e12006

History

Data availability:

Comments

Comment on this article

scite_

Cited by 11

See all cited by